Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Analysts had expected profit of $4.52 billion ... the Danish company behind weight-loss drugs Ozempic and Wegovy, topped estimates in its fourth-quarter report. Eli Lilly shares were up roughly ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...

The pharmaceutical giant also issued fiscal 2025 profit guidance ... said demand for its weight loss and diabetes drugs would not meet its lofty expectations. Notably, Eli Lilly said it plans ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates ... Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound grew to $3. ...